Immunotherapy plus chemo shows promise against stomach cancer in early trial
NCT ID NCT06808971
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing whether adding the immunotherapy drug adebrelimab to standard chemotherapy can improve outcomes for people with locally advanced stomach or gastroesophageal junction cancer. About 61 participants will receive the drug combination before and after surgery. The main goal is to see how many patients have no cancer cells left in their tumor after surgery.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
adebrelimab (an immunotherapy drug) combined with nab-paclitaxel, oxaliplatin, and tegafur gimeracil oteracil potassium capsule (chemotherapy drugs)
What this could lead to
If this works, it could offer a more effective treatment approach for locally advanced stomach cancer, potentially increasing the chance of no cancer remaining after surgery.
What could go wrong
This is a small, early-phase (Phase 2) trial with only 61 participants, so results may not apply to everyone. The combination of drugs may cause significant side effects, and it's not yet known if it improves long-term survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, 100021, China
Contact Email: •••••@•••••
Contact